Calcitriol in the management of renal osteodystrophy

• Tipo: Artigo em Revista Científica Internacional
• Data: 1996

Autores

Coburn, JW (Autor) Outra; João Frazão (Autor) Outra

Revista

Título: Seminars in Dialysis

Vol. 9

Páginas: 316-326

ISSN: 0894-0959

Editora: Wiley-Blackwell

Indexação

ISI Web of Knowledge - 14 Citações

Scopus - 17 Citações

Outras Informações

ID Authenticus: P-008-PTR

DOI: 10.1111/j.1525-139x.1996.tb00687.x

Abstract (EN): The data available at present suggest certain advantages of intermittent or "pulse" treatment with calcitriol over continuous oral treatment. Patients should have proper phosphate control (serum P < 5.5 to 6.0 mg/dL), and hypercalcemia (serum calcium >10.5 to 11.0) represents a contraindication. Doses of calcitriol above 0.75 ¿g per treatment seem most often associated with adequate suppression of iPTH levels; patients with very severe hyperparathyroidism often require larger doses. The patients must be selected appropriately and the I-PTH level can be a guide to those needing therapy, with serum calcium and phosphate levels to assess "side effects." Continued adequate phosphate control is essential and a reduction of dialysate calcium may permit use of adequate calcium salts as phosphate binders and the needed calcitriol. Yet to be answered are what I-PTH levels should be sought with treatment; some data suggest that the bone features may be suppressed more than the I-PTH levels. Further careful clinical studies are required to answer this and other important questions.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 11